Ki­ran Mazum­dar Shaw, Bio­con Chair­man and Man­ag­ing Di­rec­tor

Business Sphere - - Contents - By Our Cor­re­spon­dent

Bio­con, which re­cently posted a net profit of 19%, is look­ing at gain­ing mar­ket share and im­prove its mar­gins with greater fo­cus on its prod­uct mixes and or­gan­i­sa­tional ef­fi­cien­cies. Bio­con chair­man and man­ag­ing di­rec­tor Ki­ran Mazum­dar-Shaw says that the com­pany has out­paced the mar­ket de­spite the chal­lenges and that the phar­ma­ceu­ti­cal mar­ket needs to have a more ro­bust reg­u­la­tory set-up. Edited ex­cerpts: Q: Bio­con has said that the cur­rent reg­u­la­tory en­vi­ron­ment is im­pact­ing the In­dian phar­ma­ceu­ti­cal in­dus­try’s growth. How do you see growth for the in­dus­try this fis­cal? A: First and fore­most, I think the rea­son why the in­dus­try growth has been muted or de­clin­ing is be­cause of the reg­u­la­tory un­cer­tain­ties and con­trol con­fu­sion that the govern­ment has caused. Now, with ev­ery­thing more or less kind of ad­dressed, hope­fully the in­dus­try will re­cover. But de­spite that, Bio­con has out­paced the mar­ket be­cause we are very fo­cussed on build­ing brands. You can see that we are re­ally try­ing to be ag­gres­sive and gain both mar­ket share and build our brands. In terms of my over­all out­look on the mar­ket, I think we need to have more reg­u­la­tory ro­bust­ness, you can­not have ad-ho­cism. Sud­denly, in a sort of knee-jerk re­ac­tion you with­draw (di­a­betic drug) Piogli­ta­zone from the mar­ket and then re­voke the ban. These are wrong sig­nals for any sec­tor to deal with. We are be­com­ing a very opin­ion-led de­ci­sion-mak­ing coun­try. We don’t base it on ev­i­dence or data. Q: Bio­con has said that it is man­ag­ing the un­cer­tain­ties by op­er­a­tional ef­fi­cien­cies and mar­gin-ac­cre­tive prod­ucts. How is this? A: Cur­rency move­ments have ob­vi­ously helped us to im­prove mar­gins. We are look­ing at all the bas­ket of prod­ucts we have ever since we brought in this or­gan­i­sa­tional change where we have strate­gic busi­ness units. Busi­ness unit heads are now fo­cussing on mak­ing sure the prod­uct mix de­liv­ers the max­i­mum value, growth and prof­itabil­ity. In ad­di­tion to that, our in­sulin busi­ness has re­ally taken off in the emerg­ing mar­ket, so that’s also a very high­mar­gin busi­ness for us. Q: Can you elab­o­rate on the har­monised fil­ing strategy you are ex­plor­ing for the US and Europe? A: I can­not share too much of in­for­ma­tion on this, but will say that when we look at our in­sulin port­fo­lio, there is an op­por­tu­nity to de­rive high val­ues from that. We have looked at our other pro­grammes and we re­alised that there is a lot of merit in har­mon­is­ing de­vel­op­ment of pro­grammes be­cause it then al­lows to get to the mar­ket in a very seam­less way. Q: What are the ben­e­fits from merg­ing your clin­i­cal re­search arm Clin­i­gene with its par­ent Syn­gene? A: Ba­si­cally, there are a lot of syn­er­gies be­cause Syn­gene is of­fer­ing end-to-end so­lu­tions, which starts with dis­cov­ery, re­search and go all the way to clin­i­cal

32

Ki­ran Mazum­dar Shaw, Bio­con Chair­man and Man­ag­ing Di­rec­tor

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.